RxDoctor Payments Data

Heather Santori

Gerontology · Dunn, NCNPI 1104200815

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 59.4% of the total.

$2,355in general payments, 2019–2025

Across 139 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Johnson & Johnson$261
  • Abbott$113
  • Novo Nordisk$87
  • Boehringer Ingelheim$80
  • AstraZeneca$75
  • plus $340 from 10 others

What the payments were for

  • Food & beverage$2,33799%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,355 in reported general payments places this provider in the 85th percentile of 165 gerontology providers in North Carolina.

See all gerontology providers in North Carolina

Medicare billing

Part B allowed, 2024
$11,539
Medicare patients
94
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$49,668
BrilintaTicagrelor81$36,227
XareltoRivaroxaban19$19,284
MultaqDronedarone Hcl11$8,084
Dofetilide21$3,181
Ranolazine ErRanolazine25$1,331
Colchicine26$1,096
Bumetanide24$874
Isosorbide Mononitrate ErIsosorbide Mononitrate82$746
Metoprolol Succinate70$657
ClopidogrelClopidogrel Bisulfate48$653
SotalolSotalol Hcl60$545
Flecainide Acetate19$543
Atorvastatin Calcium39$525
Rosuvastatin Calcium44$516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$49,66859 claims
AstraZenecaBrilinta$75$36,22781 claims
Johnson & JohnsonXarelto$261$19,28419 claims
Sanofi-aventis U.S. LLCMultaq$62$8,08411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 165 gerontology providers in North Carolina.

Other gerontology in Dunn

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →